1116359-18-2 Usage
Appearance
Yellowish-brown crystalline solid The compound has a yellowish-brown color and a crystalline structure.
Melting point
181-183°C The compound transitions from a solid to a liquid state at a temperature range of 181-183°C.
Usage in organic synthesis
The compound is often used in organic synthesis, which involves the study and construction of carbon-containing molecules.
Intermediate in pharmaceutical and agricultural chemical production
1H-Inden-1-one, 2,3-dihydro-4-Methoxy-5-nitroserves as an intermediate in the production of pharmaceuticals and agricultural chemicals, meaning it is a reactant in the synthesis of these products.
Nitro and methoxy functional groups
The presence of nitro (-NO2) and methoxy (-OCH3) functional groups in the compound contributes to its reactivity and potential applications in various industries.
Potential biological and pharmacological properties
The compound may possess biological and pharmacological properties that could be significant in the fields of medicine and pharmacology, warranting further study and exploration.
Check Digit Verification of cas no
The CAS Registry Mumber 1116359-18-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,6,3,5 and 9 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1116359-18:
(9*1)+(8*1)+(7*1)+(6*6)+(5*3)+(4*5)+(3*9)+(2*1)+(1*8)=132
132 % 10 = 2
So 1116359-18-2 is a valid CAS Registry Number.
1116359-18-2Relevant academic research and scientific papers
SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
-
Page/Page column 895, (2016/04/10)
Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
Conformationally constrained analogues of N′-(4-tert-butylbenzyl)-N-(4-methylsulfonylaminobenzyl)thiourea as TRPV1 antagonists
Lim, Ju-Ok,Jin, Mi-Kyoung,Ryu, HyungChul,Kang, Dong Wook,Lee, Jeewoo,Pearce, Larry V.,Tran, Richard,Toth, Attila,Blumberg, Peter M.
experimental part, p. 322 - 331 (2009/04/07)
A series of bicyclic analogues having indan and tetrahydronaphthalene templates in the A-region were designed as conformationally constrained analogues of our previously reported potent TRPV1 antagonists (1, 3). The activities for rat TRPV1 of the conformationally restricted analogues were moderately or markedly diminished, particularly in the case of the tetrahydronaphthalene analogues. The analysis indicated that steric constraints at the benzylic position in the bicyclic analogues may be an important factor for their unfavorable interaction with the receptor.
